Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
← catalyst calendarNCT03428646 · readout in 223 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →. With Sanofi.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
858actual
Sites
99
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-04-06 | actual | When the study began enrolling |
| Primary completion | 2027-03-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-30 | estimated | The whole study's end, after follow-up |
| First posted | 2018-02-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dermatitis, Atopic
Intervention
- Drug: Dupilumab — also filed as DUPIXENT®, REGN668
Primary outcomes
what the primary-completion date above is the date OFRegistry Assessment: Baseline Characteristics
measured At baseline (day when DUPIXENT treatment is initiated)
Registry Assessment: Baseline Characteristic
measured At baseline (day when DUPIXENT treatment is initiated)
Publications
- PMID 40234297 — linked by the registry
- PMID 38175364 — linked by the registry
- PMID 35590038 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed